File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Comparison of the efficacy of lamivudine and famciclovir in Asian patients with chronic hepatitis B: Results of 24 weeks of therapy

TitleComparison of the efficacy of lamivudine and famciclovir in Asian patients with chronic hepatitis B: Results of 24 weeks of therapy
Authors
Issue Date2002
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/32763
Citation
Journal Of Medical Virology, 2002, v. 67 n. 3, p. 334-338 How to Cite?
AbstractLamivudine therapy improves hepatic necroinflammatory activity, decreases progression of fibrosis, and suppresses hepatitis B virus (HBV) replication. Famciclovir has also been shown to have some effect in the suppression of HBV replication. The aim of the study was to compare the effect of treatment with lamivudine and famciclovir on serum HBV DNA levels in patients with chronic hepatitis B and to assess safety. A prospective randomised clinical study was carried out on 100 patients with chronic hepatitis B infection (50 patients received lamivudine 100 mg daily and 50 patients received famciclovir 500 mg three times a day for 12 weeks. From the twelfth week onwards, patients were offered lamivudine 100 mg daily up to 48 weeks). Significantly more patients treated by lamivudine than by famciclovir had undetectable HBV DNA levels after 12 weeks of therapy (P < 0.001). The median HBV DNA levels were significantly lower in the lamivudine-treated patients from the second week of treatment onwards (P < 0.001 for all time points up to 12 weeks). At week 16, 4 weeks after the famciclovir treated patients were put on lamivudine, there was no longer any difference in HBV DNA levels between the two groups of patients. Both treatments were well tolerated and no serious adverse events were reported. It was concluded that in Chinese patients with chronic hepatitis B infection, lamivudine achieved effective suppression of HBV DNA levels within 4 weeks of therapy whereas famciclovir had a significantly weaker action. © 2002 Wiley-Liss, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/78223
ISSN
2015 Impact Factor: 1.998
2015 SCImago Journal Rankings: 1.015
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLai, CLen_HK
dc.contributor.authorYuen, MFen_HK
dc.contributor.authorHui, CKen_HK
dc.contributor.authorGarridoLestache, Sen_HK
dc.contributor.authorCheng, CTKen_HK
dc.contributor.authorLai, YPen_HK
dc.date.accessioned2010-09-06T07:40:31Z-
dc.date.available2010-09-06T07:40:31Z-
dc.date.issued2002en_HK
dc.identifier.citationJournal Of Medical Virology, 2002, v. 67 n. 3, p. 334-338en_HK
dc.identifier.issn0146-6615en_HK
dc.identifier.urihttp://hdl.handle.net/10722/78223-
dc.description.abstractLamivudine therapy improves hepatic necroinflammatory activity, decreases progression of fibrosis, and suppresses hepatitis B virus (HBV) replication. Famciclovir has also been shown to have some effect in the suppression of HBV replication. The aim of the study was to compare the effect of treatment with lamivudine and famciclovir on serum HBV DNA levels in patients with chronic hepatitis B and to assess safety. A prospective randomised clinical study was carried out on 100 patients with chronic hepatitis B infection (50 patients received lamivudine 100 mg daily and 50 patients received famciclovir 500 mg three times a day for 12 weeks. From the twelfth week onwards, patients were offered lamivudine 100 mg daily up to 48 weeks). Significantly more patients treated by lamivudine than by famciclovir had undetectable HBV DNA levels after 12 weeks of therapy (P < 0.001). The median HBV DNA levels were significantly lower in the lamivudine-treated patients from the second week of treatment onwards (P < 0.001 for all time points up to 12 weeks). At week 16, 4 weeks after the famciclovir treated patients were put on lamivudine, there was no longer any difference in HBV DNA levels between the two groups of patients. Both treatments were well tolerated and no serious adverse events were reported. It was concluded that in Chinese patients with chronic hepatitis B infection, lamivudine achieved effective suppression of HBV DNA levels within 4 weeks of therapy whereas famciclovir had a significantly weaker action. © 2002 Wiley-Liss, Inc.en_HK
dc.languageengen_HK
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/32763en_HK
dc.relation.ispartofJournal of Medical Virologyen_HK
dc.rightsJournal of Medical Virology. Copyright © John Wiley & Sons, Inc.en_HK
dc.subject.mesh2-Aminopurine - adverse effects - analogs & derivatives - therapeutic useen_HK
dc.subject.meshAdolescenten_HK
dc.subject.meshAdulten_HK
dc.subject.meshAntiviral Agents - adverse effects - therapeutic useen_HK
dc.subject.meshChinaen_HK
dc.subject.meshDNA, Viral - blooden_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHepatitis B Antibodies - blooden_HK
dc.subject.meshHepatitis B Surface Antigens - blooden_HK
dc.subject.meshHepatitis B e Antigens - blooden_HK
dc.subject.meshHepatitis B virus - drug effects - isolation & purification - physiologyen_HK
dc.subject.meshHepatitis B, Chronic - drug therapyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshLamivudine - adverse effects - therapeutic useen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshTreatment Outcomeen_HK
dc.titleComparison of the efficacy of lamivudine and famciclovir in Asian patients with chronic hepatitis B: Results of 24 weeks of therapyen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0146-6615&volume=67&spage=334&epage=348&date=2002&atitle=Comparison+of+the+Efficacy+of+Lamivudine+and+Famciclovir+in+Asian+Patients+with+Chronic+Hepatitis+B:+Results+of+24+Weeks+of+Therapyen_HK
dc.identifier.emailLai, CL:hrmelcl@hku.hken_HK
dc.identifier.emailYuen, MF:mfyuen@hkucc.hku.hken_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.identifier.authorityYuen, MF=rp00479en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/jmv.10075en_HK
dc.identifier.pmid12116023-
dc.identifier.scopuseid_2-s2.0-0036267550en_HK
dc.identifier.hkuros80568en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0036267550&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume67en_HK
dc.identifier.issue3en_HK
dc.identifier.spage334en_HK
dc.identifier.epage338en_HK
dc.identifier.isiWOS:000175980000006-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK
dc.identifier.scopusauthoridYuen, MF=7102031955en_HK
dc.identifier.scopusauthoridHui, CK=7202876933en_HK
dc.identifier.scopusauthoridGarridoLestache, S=6506810288en_HK
dc.identifier.scopusauthoridCheng, CTK=19642078800en_HK
dc.identifier.scopusauthoridLai, YP=19735618300en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats